Tumor grade-titude: XGBoost radiomics paves the way for RCC classification.

Journal: European journal of radiology
Published Date:

Abstract

This study aimed to develop and evaluate a non-invasive XGBoost-based machine learning model using radiomic features extracted from pre-treatment CT images to differentiate grade 4 renal cell carcinoma (RCC) from lower-grade tumours. A total of 102 RCC patients who underwent contrast-enhanced CT scans were included in the analysis. Radiomic features were extracted, and a two-step feature selection methodology was applied to identify the most relevant features for classification. The XGBoost model demonstrated high performance in both training (AUC = 0.87) and testing (AUC = 0.92) sets, with no significant difference between the two (p = 0.521). The model also exhibited high sensitivity, specificity, positive predictive value, and negative predictive value. The selected radiomic features captured both the distribution of intensity values and spatial relationships, which may provide valuable insights for personalized treatment decision-making. Our findings suggest that the XGBoost model has the potential to be integrated into clinical workflows to facilitate personalized adjuvant immunotherapy decision-making, ultimately improving patient outcomes. Further research is needed to validate the model in larger, multicentre cohorts and explore the potential of combining radiomic features with other clinical and molecular data.

Authors

  • Stephan Ellmann
    Department of Radiology, Universitätsklinikum Erlangen, 91054 Erlangen, Germany. Electronic address: stephan.ellmann@uk-erlangen.de.
  • Felicitas von Rohr
    Institute of Radiology, University Hospital Erlangen, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg, Erlangen, Germany.
  • Selim Komina
    Institute of Pathology, Faculty of Medicine, Ss Cyril and Methodius University ul. 50 Divizija bb 1000 Skopje, North Macedonia.
  • Nadine Bayerl
    Friedrich-Alexander-Universität Erlangen-Nürnberg, Institute of Radiology, University Hospital Erlangen, Maximiliansplatz 3, 91054 Erlangen, Germany. Electronic address: nadine.bayerl@fau.de.
  • Kerstin Amann
    Department of Nephropathology, Friedrich-Alexander University Erlangen-Nürnberg, Erlangen, Germany.
  • Iris Polifka
    Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg, Erlangen, Germany; Humanpathologie Dr. Weiß MVZ GmbH, Am Weichselgarten 30a, 91058 Erlangen-Tennenlohe, Germany.
  • Arndt Hartmann
    Institute of Pathology, University Hospital of Friedrich-Alexander-University Erlangen-Nürnberg, Germany.
  • Danijel Sikic
    Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany.
  • Bernd Wullich
    Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany.
  • Michael Uder
    Institute of Radiology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany.
  • Tobias Bäuerle
    Department of Radiology, Universitätsklinikum Erlangen, 91054 Erlangen, Germany. Electronic address: tobias.baeuerle@uk-erlangen.de.